Our analysis of options history for Biogen BIIB revealed 12 unusual trades. Delving into the details, we found 25% of traders ...

Eisai (ESAIY) and Biogen (BIIB) announced that the humanized anti-soluble aggregated amyloid-beta, or Abeta, monoclonal antibody Leqembi has ...

Viehbacher, "Biogen") announced today that the humanized anti-soluble aggregated amyloid-beta (Aß) monoclonal antibody "LEQEMBI®" has been launched in South Korea. LEQEMBI received the Ministry of ...

We recently published a list of 10 Cheapest Stocks to Buy On Robinhood. In this article, we are going to take a look at where ...

We recently compiled a list of the 10 Worst Performing Healthcare Stocks in 2024. In this article, we are going to take a ...

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene ...

Biogen has given up on seeking approval for its Alzheimer's disease therapy Aduhelm in the EU, saying that discussions with EU regulators had made it clear the current data for the drug is not ...

Biogen's efforts to replenish its multiple sclerosis pipeline have suffered a setback, after the FDA placed a clinical hold on a drug candidate it licensed from China's InnoCare last year for $125 ...

Nov 28, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the humanized anti- soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" has been launched in ...

Sage to abandon development of neurological disorder drug after multiple failures November 20, 2024 The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's ...

The biotechnology company, which sees itself as "pretty conservative," recently put out an ambitious long-term revenue ...